Publication

Mouse models of nonalcoholic steatohepatitis in preclinical drug development

Drug Discovery Today 22(11):1707–1718, 2017

Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K.

Share this page

Resource Library

Related resources

A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity

Hepatocyte mARC1 promotes fatty liver disease

Combinations of an Acetyl Coenzyme-A Carboxylase Inhibitor, FXR Agonist, and GLP-1R Agonist Inhibit Fibrosis Progression in the Rat Choline-Deficient, L-Amino-Acid–Defined, High-Fat Diet Model of Advanced Fibrosis

Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650